Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, October 19, 2016

Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees



abstract

Background: Drug advisory committees provide independent advice to the U.S. Food and Drug Administration (FDA) on policy matters. Committee members are special government employees and are subject to federal employee conflict-of-interest guidelines under 18 U.S.C. § 208 and § 712 (1994). Although these regulations prohibit actual or apparent conflicts of interest, regulatory policy allows waivers to be issued when the participant's expertise is deemed essential to evaluating a specific matter before the advisory committee. The issuance of waivers can be complicated, but the FDA is clear that relevant scientific expertise is a necessary and primary criterion (1). Therefore, patient and consumer representatives are ineligible to receive waivers for conflicts of interest (1). In addition, committee members with more than $50 000 in financial relationships are typically ineligible for waivers regardless of expertise.

0 comments :

Post a Comment

Your comments?